We therefore propose that development of brain penetrating PHD inhibitors, with and without additional activity versus FIH (which contributes to regulation of the set of HIF target genes), is pursued with a view to investigating their potential for AD treatment, via alteration of synaptic function in the hippocampus, either mediated via EPO upregulation or not. This evidence concerns the gene PDC and Alzheimer disease.